Skip to content

A Randomized Controlled Non-inferiority Trial on the Effect of Low-Dose Mivacurium with Optimized Administration Timing on Intubation Conditions for Suspension Laryngoscopy Surgery

A Randomized Controlled Non-inferiority Trial on the Effect of Low-Dose Mivacurium with Optimized Administration Timing on Intubation Conditions for Suspension Laryngoscopy Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122812
Enrollment
Unknown
Registered
2026-04-17
Start date
2026-04-19
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspension laryngoscopy surgery

Interventions

Experimental group:At time T0, administer 0.15 mg/kg of mivacurium. Administer sedation at 60 seconds after T0. Insert the tube at 240 seconds after T0.
Control group:At T0, administer 0.2 mg/kg mivacurium chloride. At T0 + 60 seconds, insert the tube.

Sponsors

The General Hospital of the Northern Theater Command of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 - 65 years old. 2. ASA classification: Grade I or II. 3. Scheduled for laryngeal surgery under general anesthesia with a laryngeal support device. 4. Body Mass Index (BMI): 18.5 - 28.0 kg/m^2. 5. Voluntary participation and signing of a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Predicted as a difficult airway (Mallampati grade = III, mouth opening < 3 cm, mentohyoid distance < 6 cm, or with a clear history of difficult airway). 2. Known to be allergic to propofol, remifentanil, and mivacurium. 3. Severe liver and kidney dysfunction. 4. Suffering from neuromuscular disorders. 5. Pregnant or lactating women. 6. Long-term use of drugs that affect neuromuscular conduction. 7. Other conditions judged by the researcher as not suitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Total Cooper score for tracheal intubation conditions (score range: 4–12);

Secondary

MeasureTime frame
Onset time;Clinical duration;Recovery index;Time from drug discontinuation to TOF >= 0.9;TOF ratio at extubation;PACU length of stay;Area under the curve (AUC) for MAP below 20% of baseline;Incidence of intraoperative body movements requiring intervention;Proportion of patients who did not receive neuromuscular blocking reversal agents;Incidence of required assisted ventilation during the induction period (experimental group);Incidence of sore throat;Incidence of PONV;Patient and surgeon satisfaction;QoR-15 at 24 hours postoperatively;

Countries

China

Contacts

Public ContactDiao Yugang

The General Hospital of the Northern Theater Command of the People's Liberation Army of China

hongnafan@163.com+86 24 2885 1365

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026